Filana Therapeutics Names Biopharma Executive Jill M. Quigley to Board
Key Highlights
- ➤Filana Therapeutics (FLNA) appoints Jill M. Quigley to its Board of Directors
- ➤Phase 2a simufilam study screening expected to begin by first quarter 2027
- ➤Quigley brings more than 20 years of biotechnology industry leadership experience
- ➤Simufilam remains an investigational candidate for TSC-related epilepsy
Expert Statements
Claude Nicaise, MD and Chairman of the Board of Filana Therapeutics
“On behalf of the Board, I welcome Jill to Filana. Her record of guiding companies through financings and strategic growth will broaden the expertise around our Board table”
Claude Nicaise, MD and Chairman of the Board of Filana Therapeutics
“This appointment reflects our continued focus on aligning the Board with Filana Therapeutics’ evolving needs as the Company moves simufilam through clinical development.”
Rick Barry, President and Chief Executive Officer of Filana Therapeutics, Inc.
“Jill joins Filana at an exciting time, as we prepare for our planned Phase 2a clinical study of simufilam in TSC-related epilepsy, with patient screening expected to begin by the first quarter of 2027”
Rick Barry, President and Chief Executive Officer of Filana Therapeutics, Inc.
“We believe in the scientific rationale supporting our program in TSC, and I look forward to collaborating closely with Jill as we work to create value for patients, their families, and shareholders.”
Jill M. Quigley, Independent Director of Filana Therapeutics
“I am pleased to join the Filana Therapeutics Board and eager to contribute my experience as the Company advances simufilam through clinical development. I have been particularly impressed by Filana’s commitment to patients and its science-driven approach to developing a potential new treatment for TSC-related epilepsy.”
AUSTIN, Texas, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA), a biotechnology company focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced the appointment of Jill M. Quigley to its Board of Directors (the “Board”). Ms. Quigley brings additional executive leadership experience to Filana, having previously scaled biopharma companies through pivotal stages of drug development, financing, and value creation.
“On behalf of the Board, I welcome Jill to Filana. Her record of guiding companies through financings and strategic growth will broaden the expertise around our Board table,” commented Claude Nicaise, MD, Chairman of the Board of Filana Therapeutics. “This appointment reflects our continued focus on aligning the Board with Filana Therapeutics’ evolving needs as the Company moves simufilam through clinical development.”
Get started
Create a free account to read the full story.